LEVEL OF SODIUMURETIC PEPTIDE IN EARLY DIAGNOSIS OF CHRONIC HEART FAILURE IN PATIENTS WITH ARTERIAL HYPERTENSION

Chronic heart failure (CHF) is the most common and serious complication of cardiovascular disease. Arterial hypertension is the most common cause of CHF. The study of the problem of heart failure in the early stages of its development is of particular interest to clinicians. At the same time, the diagnosis of CHF in the early stages is important to prevent its further progression. To date, data have appeared on the possibility of early diagnosis of CHF of any etiology and predicting the occurrence of unfavorable outcomes of heart failure using brain natriuretic peptide - B - type Natriuretik Peptide (BNP) In recent years, as a marker of the early (preclinical) stage of CHF in patients with arterial hypertension group B natriuretic peptide (BNP) is used. Serum BNP is becoming the standard in the early diagnosis of CHF. The main stimulus for increased BNP secretion is left ventricular volume overload. Natriuretic peptides (NP) are physiological angiotensin II antagonists in relation to the stimulation of aldosterone secretion. An increase in plasma renin activity and aldosterone concentration causes left ventricular remodeling, accumulation of fibrous tissue, and ventricular overload. The main trigger for BNP is increased myocardial tension